Tuberculosis recurrence: Multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors

Clinical Infectious Diseases

Volumn 32, Issue 3, 2001, Pages 515-517

  Narita, Masahiro ^a,c,d   Hisada, Michie ^b   Thimmappa, Brinda ^b   Stambaugh, Jerry J ^a   Ibrahim, Emad ^a   Hollender, Elena S ^a,c   Ashkin, David ^a,c,d  

^a A G Holley State Tuberculosis Hospital   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; CHILD; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MALE; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; BLOTTING, WESTERN; CD4 LYMPHOCYTE COUNT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV ANTIBODIES; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; RISK FACTORS; TUBERCULOSIS; VIRAL LOAD;

EID: 0035116796     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/318490     Document Type: Article

References (9)

1. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations
2. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis
3. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients
4. Low serum antimycobacterial drug levels in non-HIV infected tuberculosis patients
5. A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong
6. Treatment of tuberculosis and tuberculosis infection in adults and children
7. Using therapeutic drug monitoring to dose the antimycobacterial drugs
8. Risk of pulmonary tuberculosis relative to silicosis and exposure to silica dust in South African Gold Miners
9. Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients